| 000 | 00960 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250515014309.0 | ||
| 264 | 0 | _c20060307 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a1539-3704 | ||
| 024 | 7 |
_a10.7326/0003-4819-144-3-200602070-00028 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMusher, Daniel M | |
| 245 | 0 | 0 |
_aUndisclosed conflicts of interest. _h[electronic resource] |
| 260 |
_bAnnals of internal medicine _cFeb 2006 |
||
| 300 |
_a225; author reply 225-6 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 | _aConflict of Interest |
| 650 | 0 | 4 |
_aHeptanoic Acids _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrroles _xtherapeutic use |
| 773 | 0 |
_tAnnals of internal medicine _gvol. 144 _gno. 3 _gp. 225; author reply 225-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7326/0003-4819-144-3-200602070-00028 _zAvailable from publisher's website |
| 999 |
_c16075114 _d16075114 |
||